Program
acasunlimab
Also written as “Acasunlimab”, “Acasunlimab in combination with docetaxel (in a single expansion cohort)” and “Acasunlimab in combination with pembrolizumab (in a separate expansion cohort)”.
Its studies are mostly in Lung Neoplasms · Melanoma · Carcinoma, Non-Small-Cell Lung · Endometrial Neoplasms, led by Genmab.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Genmab | 61 open or running | phase 3since Oct 8, 2024 | Apr 11, 2019 | Jul 30, 2027phase 3 · NCT06635824 |
Also a collaborator on its studies: Merck and BioNTech.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 11, 2019First study: phase 2 study in Solid TumorsFirst studyNCT03917381 · 429 enrolled · United States, Czechia, Georgia and more
- May 11, 2021Phase 1 study in Solid TumorNCT04937153 · 18 enrolled · Japan
- Nov 1, 2021Phase 2 study in Non Small Cell Lung Cancer MetastaticNCT05117242 · 125 enrolled · United States, France, Germany and more
- Sep 14, 2023Phase 2 study in Advanced Endometrial CancerNCT06046274 · United States, Belgium, Denmark and more
- Oct 8, 2024Phase 3 study in Lung NeoplasmsNCT06635824 · 191 enrolled · United States, Argentina, Australia and more
- May 14, 2025Phase 2 study in MelanomaNCT06984328 · 1 enrolled · United States, Puerto Rico
Ahead
- Jul 30, 2027Primary completion: phase 3 study in Lung NeoplasmsNCT06635824
TargetBeta
“A recombinant, Fc-silenced immunoglobulin G1 (IgG1) bispecific antibody targeting both the human programmed death-ligand 1 (PD-L1) and 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9), ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-PD-L1/4-1BB Bispecific Antibody LBL-024rule | nanjing-leads-biolabs-co-ltd | phase 3 | 10 |
| Anti-CD137/PD-L1 Bispecific Antibody FS222 | Sino Biopharmaceutical | phase 1 | 1 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06984328Melanoma · United States, Puerto Rico | 2 | Terminated | May 15, 2026 | 1 |
| NCT06635824Lung Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jul 30, 2027 | 191 |
| NCT06046274Advanced Endometrial Cancer · United States, Belgium, Denmark and more | 2 | Withdrawn | Apr 1, 2028 | 0 |
| NCT05117242Non Small Cell Lung Cancer Metastatic · United States, France, Germany and more | 2 | Terminated | Dec 2, 2024 | 125 |
| NCT04937153Solid Tumor · Japan | 1 | Completed | Oct 1, 2024 | 18 |
| NCT03917381Solid Tumors · United States, Czechia, Georgia and more | 2 | Terminated | Apr 1, 2025 | 429 |
How it is read
Names in the registry
- “Acasunlimab”, 6 entries
- “Acasunlimab in combination with docetaxel (in a single expansion cohort)”, 1 entry
- “Acasunlimab in combination with pembrolizumab (in a separate expansion cohort)”, 1 entry
- “Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts)”, 1 entry
Conditions, from the studies’ own filings
- Lung Neoplasms, 1 study
- Melanoma, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
- Endometrial Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.